Tvardi Therapeutics, Inc. Common Stock
TVRDTvardi Therapeutics, Inc. is a biotechnology company focused on developing targeted therapies for inflammatory and fibrotic diseases. The company leverages its proprietary drug discovery platform to identify and advance small-molecule treatments aimed at challenging conditions, with an emphasis on improving patient outcomes.
$4.55 +0.19 (4.41%)
Company News
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
Tvardi Therapeutics (NASDAQ: TVRD) experienced an 80% stock decline on October 13, 2025, after disappointing preliminary data from its Phase 2 REVERT clinical trial of TTI-101 for idiopathic pulmonary fibrosis. The study failed to meet its primary goals regarding safety and lung function outcomes. A securities law firm is now investigating potent...
